Acinetobacter baumannii complex-Introduction, Morphology, Pathog

Introduction

Table of Contents

Acinetobacter baumannii complex is a group of Gram-negative, non-fermenting bacilli known for causing healthcare-associated infections. It includes closely related species like A. baumannii, A. pittii, A. nosocomialis, and A. calcoaceticus. This complex thrives in hospital environments and poses a serious challenge due to its multidrug resistance and persistence on surfaces.

Morphology

Gram-negative coccobacilli (short rods)
Non-motile and oxidase-negative
Catalase-positive
Appears as diplococci under Gram stain, often confused with Neisseria or Moraxella
Forms smooth, opaque, dome-shaped colonies on nutrient agar or MacConkey agar (non-lactose fermenting)

Pathogenicity

Causes opportunistic infections, especially in immunocompromised patients
Major infections: ventilator-associated pneumonia (VAP), bloodstream infections (BSI), urinary tract infections, wound infections, and meningitis
Adheres to epithelial cells and abiotic surfaces via pili and outer membrane proteins
Produces enzymes like β-lactamases, and forms biofilms that aid in resistance and survival
Known for its role in outbreaks in ICU settings

Laboratory Diagnosis

Specimen types: Blood, sputum, tracheal aspirates, wound swabs, urine
Culture: Grows well on blood agar and MacConkey agar
Gram stain: Shows Gram-negative coccobacilli
Biochemical tests: Oxidase-negative, catalase-positive, non-motile, glucose non-fermenter
MALDI-TOF MS: Rapid and accurate identification
Molecular methods (PCR, sequencing): Used to differentiate species within the complex
Antibiotic susceptibility testing (AST): Essential due to frequent multidrug resistance

Treatment

Multidrug resistance is common (MDR, XDR, and PDR strains)
Preferred agents (depending on susceptibility):
- Carbapenems (e.g., meropenem) — although resistance is increasing
- Polymyxins (colistin, polymyxin B) are often last-resort drugs.
- Tigecycline, minocycline, sulbactam, cefiderocol — in resistant strains
Combination therapy may be considered in severe infections
Antimicrobial stewardship and local antibiogram guide therapy

Prevention

Strict hand hygiene and contact precautions
Environmental disinfection (it survives on surfaces for weeks)
Surveillance and cohorting during outbreaks
Rational antibiotic use to prevent resistance development
Use of sterile devices and aseptic techniques in ICUs

Keynotes

A. baumannii complex causes severe infections in critically ill patients
Its remarkable environmental resilience and antibiotic resistance make it a “red alert” pathogen (WHO priority list)
Early identification and AST-guided treatment are crucial
Molecular tools help differentiate between species in the complex
Prevention hinges on infection control and antibiotic policy compliance
Late lactose-fermenting, gram-negative coccobacilli, non-motile, are the key features of Acinetobacter.

Acinetobacter baumannii complex-Introduction, Morphology, Pathogenicity, Lab Diagnosis, Treatment, Prevention, and Keynotes